2023
Prevalence and Correlates of Physical Inactivity Among Individuals with HIV During the First COVID-19 Wave: A Cross-sectional Survey
Harsono D, Deng Y, Chung S, Barakat L, Friedland G, Villanueva M, Yager J, Justen M, Edelman E. Prevalence and Correlates of Physical Inactivity Among Individuals with HIV During the First COVID-19 Wave: A Cross-sectional Survey. AIDS And Behavior 2023, 28: 1531-1545. PMID: 37824037, PMCID: PMC11349050, DOI: 10.1007/s10461-023-04170-5.Peer-Reviewed Original ResearchPhysical activity guidelinesPhysical inactivityPhysical activityDetectable HIV viral loadSelf-reported physical activitySample of PWHHIV viral loadPhysical activity levelsUnhealthy alcohol useFirst COVID-19 waveImproved health outcomesCross-sectional surveyHIV clinicCOVID-19 waveActivity guidelinesAdjusted analysisCOVID-19 transmissionViral loadTobacco useCoping strategiesSedentary lifestyleLower oddsPsychological coping strategiesHealth outcomesDisease controlDectin-1 stimulation promotes a distinct inflammatory signature in the setting of HIV-infection and aging
Kumar A, Wang J, Esterly A, Radcliffe C, Zhou H, Wyk B, Allore H, Tsang S, Barakat L, Mohanty S, Zhao H, Shaw A, Zapata H. Dectin-1 stimulation promotes a distinct inflammatory signature in the setting of HIV-infection and aging. Aging 2023, 15: 7866-7908. PMID: 37606991, PMCID: PMC10497004, DOI: 10.18632/aging.204927.Peer-Reviewed Original ResearchConceptsDectin-1 stimulationDendritic cellsHIV-positive older adultsOlder adultsDectin-1 functionDistinct immune signaturesDistinct inflammatory signatureMonocytes of HIVCohort of HIVIFN-α productionPro-inflammatory environmentIFN-γ responsesPro-inflammatory phenotypeInnate immune receptorsDistinct gene signaturesStimulation of monocytesInflammatory signatureImmune signaturesHIV infectionIL-12Macrophage signatureCytokine productionIL-6Cytokine increaseHIVExpanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach?
Hao R, Brooks R, Zelenev A, Spinner G, Barakat L, Villanueva M. Expanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach? Health Promotion Practice 2023, 24: 1009-1017. PMID: 37439817, DOI: 10.1177/15248399231169794.Peer-Reviewed Original ResearchConceptsHepatitis C virusRisk factor-based screeningElectronic medical recordsHIV clinicAnnual screeningC virusRisk factorsScreening siteAnnual screening ratesNew HCV diagnosesClinical decision support toolRisk factor assessmentPublic health expertsHCV testingHCV casesClinical decision supportHCV diagnosisHCV testScreening ratesProspective studyMedical recordsPositivity ratePositive casesUnprotected sexClinicBuilding an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections
Gleeson S, Zapata H, Bathgate M, Emu B, Frederick J, Friedland G, Golden M, Meyer J, Radin J, Sideleau R, Shaw A, Shenoi S, Trubin P, Virata M, Barakat L, Desruisseaux M. Building an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections. Clinical Infectious Diseases 2023, 77: 703-710. PMID: 37078888, DOI: 10.1093/cid/ciad236.Peer-Reviewed Original ResearchConceptsEducational activitiesHealthcare inequitiesInfectious Diseases SectionSingle-center experienceCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicMixed-methods assessmentLearning objectivesPilot curriculumEducational trainingCurriculumCenter experienceLong-term behavioral changesProgram outcomesDisease sectionDisease diversityPhysician perspectivesResponse rateHealth disparitiesYale SchoolInequitiesAntiracismBehavioral changesRacismEquityHIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report
Ogbuagu O, Sharma M, Igiraneza G, Andrews L, Tuan J, Barakat L. HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report. BMC Infectious Diseases 2023, 23: 146. PMID: 36890468, PMCID: PMC9993362, DOI: 10.1186/s12879-023-08075-5.Peer-Reviewed Original ResearchConceptsHIV risk profilesSTI riskPre-exposure prophylaxis useRisk profileMedian age 28 yearsHIV-negative respondentsHIV-negative participantsHIV-negative individualsReceptive anal intercourseModerate alcohol useAge 28 yearsCross-sectional surveySexual partner numberProphylaxis useResultsEighty-onePrEP knowledgeHIV positivityPrevention gapUrban clinicCenter clinicPrevention needsSTI historyInclusion criteriaAnal intercourseIllicit substancesEquity and use of telehealth modalities among people living with HIV during the COVID-19 pandemic
Carson H, Wang K, Paek H, Hoffman P, Arakaki A, Gonzalez-Colaso R, Barakat L, Villanueva M, Womack J. Equity and use of telehealth modalities among people living with HIV during the COVID-19 pandemic. Digital Health 2023, 9: 20552076231218840. PMID: 38107977, PMCID: PMC10722925, DOI: 10.1177/20552076231218840.Peer-Reviewed Original Research
2022
Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
Tuan JJ, Zapata H, Barakat L, Andrews L, Behnegar A, Kim YW, Kayani J, Mutic S, Ryall L, Turcotte B, Critch-Gilfillan T, Zhao M, Salahuddin S, Gupta S, Sutton R, Friedland G, Emu B, Ogbuagu O. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infectious Diseases 2022, 22: 744. PMID: 36131232, PMCID: PMC9491266, DOI: 10.1186/s12879-022-07737-0.Peer-Reviewed Original ResearchConceptsT cell responsesAnti-spike IgGVisit 3SARS-CoV-2Older PWHVisit 2Immune responseSingle-center longitudinal observational studyVirus-specific T cell responsesVaccine-induced humoral immunityLong-term protective immunityT cell immune responsesOlder peopleMedian age 61RBD IgG levelsPrimary study outcomeCOVID-19 vaccinationImmune response evaluationLongitudinal observational studyCOVID-19 vaccineWilcoxon signed-rank testBNT162b2 boosterBNT162b2 vaccinationCD8 responsesDetectable CD4Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.Peer-Reviewed Original ResearchConceptsTDF/FTCTenofovir disoproxil fumarateCoronavirus disease 2019 (COVID-19) outcomesTAF/FTCAntiretroviral therapyTenofovir alafenamideDisoproxil fumarateRisk ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCOVID-19 ICU admissionsIntensive care unit admissionPrevious COVID-19 diagnosisSyndrome coronavirus 2 infectionCOVID-19-related hospitalizationVeterans Aging Cohort StudySARS-CoV-2 infectionCare unit admissionCoronavirus 2 infectionChronic kidney diseaseHIV viral loadGlomerular filtration rateAging Cohort StudyCorresponding risk ratioPooled logistic regressionWillingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey
Wickersham JA, Meyer JP, Shenoi S, Altice FL, Barakat LA, Virata M, Olivares M, Maviglia F, Khati A, Shrestha R. Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey. Frontiers In Medicine 2022, 9: 886936. PMID: 35847816, PMCID: PMC9280331, DOI: 10.3389/fmed.2022.886936.Peer-Reviewed Original ResearchCOVID-19 infectionCOVID-19 vaccineCOVID-19Undetectable HIV viral loadCOVID-19 vaccination uptakeAnnual influenza vaccinationHIV viral loadVaccine-related concernsNational surveyHIV careInfluenza vaccinationVaccination uptakeViral loadVaccination programSevere diseasePWHVaccineHIVInfectionIntensive outreach effortsTotal populationUnited StatesParticipantsAnnual incomeVast majorityLongitudinal Improvements in Viral Suppression for Persons With New HIV Diagnosis Receiving Care in the Ryan White Program: A 10-Year Experience in New Haven, CT (2009–2018)
Zhao A, Rizk C, Zhao X, Esu A, Deng Y, Barakat L, Villanueva M. Longitudinal Improvements in Viral Suppression for Persons With New HIV Diagnosis Receiving Care in the Ryan White Program: A 10-Year Experience in New Haven, CT (2009–2018). Open Forum Infectious Diseases 2022, 9: ofac196. PMID: 35794946, PMCID: PMC9251657, DOI: 10.1093/ofid/ofac196.Peer-Reviewed Original ResearchViral suppressionHIV care continuumHIV diagnosisNew HIV diagnosesART initiationPrimary careCare continuumGreater New Haven areaHIV primary careRyan White ProgramAntiretroviral therapy initiationInhibitor-containing regimensLongitudinal improvementRecent HIV diagnosisComprehensive care modelNew Haven areaCase management servicesElectronic medical recordsEligible patientsPC visitsTherapy initiationPrimary outcomeMedical recordsWhite ProgramMedian numberCOVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey
Shrestha R, Meyer JP, Shenoi S, Khati A, Altice FL, Mistler C, Aoun-Barakat L, Virata M, Olivares M, Wickersham JA. COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey. Vaccines 2022, 10: 424. PMID: 35335054, PMCID: PMC8949562, DOI: 10.3390/vaccines10030424.Peer-Reviewed Original ResearchCOVID-19 vaccine hesitancyVaccine hesitancySevere COVID-19 diseaseMean timeSample of PWHCells/mm3COVID-19 historyVaccine-related concernsGreater vaccine hesitancyCOVID-19 vaccineCOVID-19COVID-19 diseaseLower vaccine hesitancyCross-sectional online surveyCD4 countAssociated FactorsSide effectsHIVKey populationsPWHMultivariate linear regressionVaccineCOVID-19 epidemicHesitancyMost participantsExperiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study
Harsono D, Deng Y, Chung S, Barakat LA, Friedland G, Meyer JP, Porter E, Villanueva M, Wolf MS, Yager JE, Edelman EJ. Experiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study. AIDS And Behavior 2022, 26: 2099-2111. PMID: 35064390, PMCID: PMC8782707, DOI: 10.1007/s10461-021-03556-7.Peer-Reviewed Original ResearchConceptsHIV careRe-engage patientsMixed-methods studyCare team membersRoutine clinical experienceCOVID-19 pandemicBenefits of telemedicineHIV clinicTelemedicine visitsTelemedicine appointmentsReimbursement concernsClinical experienceClinical staffCareAppropriate billingPatientsPWHTelemedicinePatient remote monitoringReimbursement methodsPandemicHIVClinicVisitsLongitudinal Improvements in Viral Suppression for Persons with New HIV Diagnosis Receiving Care in the Ryan White Program: A 10-year experience in New Haven, CT (2009-2018)
33. Zhao A, Rizk Ch, Zhao X, Esu A, Deng Y, Barakat LA, Villanueva M. Open Forum Infectious Diseases, 2022. https://doi.org/10.1093/ofid/ofac196Peer-Reviewed Original Research
2021
856. Barriers to PrEP Implementation among Patient-Facing Staff in Three Urban Clinics
Shenoi S, Sideleau R, McKay S, Aoun-Barakat L. 856. Barriers to PrEP Implementation among Patient-Facing Staff in Three Urban Clinics. Open Forum Infectious Diseases 2021, 8: 519-519. DOI: 10.1093/ofid/ofab466.1051.Peer-Reviewed Original ResearchPrEP implementationPrEP uptakeSafety of PrEPQualified health centersLack of insuranceMultidisciplinary team membersDuration of employmentGuidelines/protocolsPrEP efficacyPrEP servicesMedian durationPrEP useUrban clinicPrEP rolloutHealth centersSafety dataProvider trainingPatient outreachSide effectsSystemic barriersMultidisciplinary staffSexual riskPatientsBehavioral interventionsPrescribersCumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study
Virata MD, Shenoi SV, Ladines-Lim J, Villanueva MS, Barakat LA. Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study. PLOS ONE 2021, 16: e0260251. PMID: 34851963, PMCID: PMC8635326, DOI: 10.1371/journal.pone.0260251.Peer-Reviewed Original ResearchConceptsOne-year retrospective cohort studyCohort of PWHNon-communicable comorbiditiesPredictors of hospitalizationRetrospective cohort studyChronic lung diseaseLikelihood of hospitalizationSingle-site experienceCOVID-19 infectionNon-communicable diseasesOutcomes of peopleCohort studyHIV diseaseOverall mortalityClinical outcomesLung diseaseCardiovascular diseaseHospitalizationCumulative burdenHIVLater timeframeDiseaseEarly epidemicPWHOutcomesHigh HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities
Ogbuagu O, Wachekwa I, Yasin F, Nuta C, Donato S, Toomey J, Adeiza M, Barakat LA. High HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities. Annals Of Global Health 2021, 87: 117. PMID: 34900617, PMCID: PMC8622250, DOI: 10.5334/aogh.3243.Peer-Reviewed Original ResearchConceptsHIV testing dataNon-pregnant individualsHIV detection rateTertiary facilityPrevention interventionsJohn F. Kennedy Medical CenterHospital-based retrospective analysisSignificant public health challengeStudy periodAnnual diagnosis ratePre-exposure prophylaxisPositive HIV testLarge tertiary hospitalCase detection ratePublic health challengeYears of ageNational prevalence estimatesDetection rateHIV/AIDSAntenatal clinicHIV testHIV testingTertiary hospitalPregnant womenUNAIDS 95Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV
Tuan JJ, Zapata H, Critch‐Gilfillan T, Ryall L, Turcotte B, Mutic S, Andrews L, Roh ME, Friedland G, Barakat L, Ogbuagu O. Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV. HIV Medicine 2021, 23: 178-185. PMID: 34632695, PMCID: PMC8652674, DOI: 10.1111/hiv.13188.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineCOVID-19 vaccinationFirst doseSeroconversion ratesSecond doseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionYale New Haven Health SystemPrior COVID-19 infectionSyndrome coronavirus 2 infectionSafe COVID-19 vaccineIntegrase strand transfer inhibitorsAnti-spike IgGPositive IgG responseTwo-dose seriesCoronavirus 2 infectionVaccine-induced immunityDurability of protectionCOVID-19 infectionStrand transfer inhibitorsAntiretroviral regimenBNT162b2 vaccineNew seroconversionsPositive IgGQualitative antibodyVZV myelitis with secondary HIV CSF escape
Weiss JJ, Spudich S, Barakat L. VZV myelitis with secondary HIV CSF escape. BMJ Case Reports 2021, 14: e241738. PMID: 34187795, PMCID: PMC8245447, DOI: 10.1136/bcr-2021-241738.Peer-Reviewed Case Reports and Technical NotesConceptsVaricella-zoster virusCSF escapeVZV myelitisSkin lesionsCerebrospinal fluidCSF HIV viral loadRight upper extremity weaknessCentral nervous system infectionSubsequent oral therapyUpper extremity weaknessHIV viral loadNervous system infectionVesicular skin lesionsCopies/mLDirect fluorescent antibody testingFluorescent antibody testingIntravenous acyclovirVZV PCRExtremity weaknessOral therapyRare complicationSystem infectionAtypical presentationImmunosuppressed patientsVZV infectionRace and ethnicity do not impact eligibility for remdesivir: A single-center experience
Pischel L, Walelo M, Benson J, Osborn R, Schrier R, Tuan J, Barakat L, Ogbuagu O. Race and ethnicity do not impact eligibility for remdesivir: A single-center experience. PLOS ONE 2021, 16: e0250735. PMID: 33956849, PMCID: PMC8101938, DOI: 10.1371/journal.pone.0250735.Peer-Reviewed Original ResearchConceptsClinical trialsExclusion criteriaSingle health care systemObservational cohort studySingle-center experienceClinical trial criteriaTime of presentationMedical record chartsNon-Hispanic whitesEthnic minority enrollmentSimilar ratesHealth care systemCohort studyTrial criteriaMultiple therapiesInclusion criteriaRecord chartsEthnic groupsRemdesivirCare systemTrialsSelf-identified WhiteEligibilityWhite participantsMultiple potential barriersLower Gastrointestinal Syphilis: Case Series and Literature Review
Ferzacca E, Barbieri A, Barakat L, Olave MC, Dunne D. Lower Gastrointestinal Syphilis: Case Series and Literature Review. Open Forum Infectious Diseases 2021, 8: ofab157. PMID: 34631920, PMCID: PMC8494075, DOI: 10.1093/ofid/ofab157.Peer-Reviewed Original ResearchHuman immunodeficiency virusAdditional casesCommon physical examination findingsAnal sexual contactLower gastrointestinal symptomsChronic inflammatory infiltrateInflammatory bowel diseasePhysical examination findingsPercent of specimensAnal painAnorectal massAnorectal ulcersNontreponemal titersGastrointestinal symptomsRectal massSyphilis infectionBowel diseaseRare manifestationCase seriesInflammatory infiltrateEarly syphilisExamination findingsImmunodeficiency virusMucosal abnormalitiesMedical records